Clinical Edge Journal Scan

Rheumatoid arthritis increases mortality risk in chronic kidney disease


 

Key clinical point: Patients with both chronic kidney disease (CKD) and rheumatoid arthritis (RA) were at an increased risk for mortality compared with those with CKD alone, with RA having no impact on progressive renal decline.

Major finding: Presence of both CKD and RA vs. CKD alone was associated with an increased risk for all-cause mortality (adjusted hazard ratio [aHR] 1.73; 95% CI 1.27-2.35) and composite of myocardial infarction, cerebrovascular accident, heart failure, or death (aHR 1.65; 95% CI 1.27-2.15), without significantly increasing the risk for progressive renal decline.

Study details: The data come from a retrospective study including 3333 patients with CKD from the Chronic Renal Insufficiency Cohort (CRIC) study, of which 83 patients had RA and were taking a disease-modifying antirheumatic therapy.

Disclosures: CRIC study was supported by the US National Institute of Diabetes and Digestive and Kidney Diseases. No conflicts of interest were declared.

Source: Ezeanuna MN et al. Association of rheumatoid arthritis with mortality in chronic kidney disease: a cohort study. Clin Rheumatol. 2022 (May 25). Doi: 10.1007/s10067-022-06223-x

Recommended Reading

Hydroxychloroquine risk found in some older patients with RA
MDedge Rheumatology
No more ‘escape hatch’: Post Roe, new worries about meds linked to birth defects
MDedge Rheumatology
Efficacy of tofacitinib independent of baseline BMI in moderate-to-severe RA
MDedge Rheumatology
RA: Obefazimod (ABX464) shows promise in phase 2
MDedge Rheumatology
Tapering rituximab dose is a valid option in RA patients with comorbidities
MDedge Rheumatology
RA: No increased risk for malignancy with tofacitinib vs. TNFi in real world
MDedge Rheumatology
Genetic liability to RA and cardiovascular risk: What is the link?
MDedge Rheumatology
Methotrexate reduces risk for mortality in rheumatoid arthritis
MDedge Rheumatology
Joint-inflammation trajectories differ by SDFR status in ACPA-positive and ACPA-negative RA
MDedge Rheumatology
Real-world study evaluates benefits of treat-to-target therapy for BMD loss in RA
MDedge Rheumatology